Febuxostat-d9
- CAS No.
- 1246819-50-0
- Chemical Name:
- Febuxostat-d9
- Synonyms
- TMX 67-d9;TEI 6720-d9;Febuxostat-d;Febuxostat-d9;D9-Febuxostat;[2H9]-Febuxostat;Dapagliflozin Impurity 138;Febuxostat-d9 (2-methylpropoxy-d9);2-(3-Cyano-4-isobutyloxyphenyl-d9)-4-Methyl-5-thiazolecarboxylic Acid;2-[3-Cyano-4-(2-Methylpropoxy-d9)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
- CBNumber:
- CB22508843
- Molecular Formula:
- C16H16N2O3S
- Molecular Weight:
- 316.37484
- MDL Number:
- MFCD21363615
- MOL File:
- 1246819-50-0.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Febuxostat-d9 ≥99%deuteratedforms(d1-d9) | 25033 | 1mg | $288 |
| Febuxostat-d9 ≥99% deuterated forms (d1-d9) | 25033 | 1mg | $261 |
| Febuxostat-d9 | TRC-F229002-1MG | 1mg | $233 |
| Febuxostat-d9 | TRC-F229002-10MG | 10mg | $1719 |
| Febuxostat-d9 98.70% | CS-4034 | 1mg | $217 |
| More product size | |||
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P264-P270-P301+P312-P330-P501 | |||||||||
| NFPA 704 |
|
Febuxostat-d9 price More Price(10)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 25033 | Febuxostat-d9 ≥99%deuteratedforms(d1-d9) | 1246819-50-0 | 1mg | $288 | 2026-04-30 | Buy |
| Cayman Chemical | 25033 | Febuxostat-d9 ≥99% deuterated forms (d1-d9) | 1246819-50-0 | 1mg | $261 | 2024-03-01 | Buy |
| TRC | TRC-F229002-1MG | Febuxostat-d9 | 1246819-50-0 | 1mg | $233 | 2026-06-03 | Buy |
| TRC | TRC-F229002-10MG | Febuxostat-d9 | 1246819-50-0 | 10mg | $1719 | 2026-06-03 | Buy |
| ChemScene | CS-4034 | Febuxostat-d9 98.70% | 1246819-50-0 | 1mg | $217 | 2026-06-04 | Buy |
Febuxostat-d9 Chemical Properties,Uses,Production
Description
Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase. It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively). It is 10-30 times more potent than the hypoxanthine analog allopurinol (; Kis = 0.7 nM and 0.7 μM, respectively). Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg). It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day. Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE). Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.
Uses
Febuxostat-d9 is a Labeled compound, intended for use as an internal standard for the quantification of Febuxostat by GC- or LC-mass spectrometry.
Uses
Labelled Febuxostat (F229000). Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout.
References
[1] KEN OKAMOTO. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.[J]. The Journal of Biological Chemistry, 2003, 278 3: 1848-1855. DOI: 10.1074/jbc.m208307200
[2] YOSHIO OSADA. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents[J]. European journal of pharmacology, 1993, 241 2: Pages 183-188. DOI: 10.1016/0014-2999(93)90201-r
[3] YASUHIRO TAKANO . Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase[J]. Life sciences, 2005, 76 16: Pages 1835-1847. DOI: 10.1016/j.lfs.2004.10.031
[4] MANISHA BISHT S S B. Febuxostat: a novel agent for management of hyperuricemia in gout.[J]. Indian Journal of Pharmaceutical Sciences, 2011, 73 6: 597-600. DOI: 10.4103/0250-474x.100231
[5] YUSUKE NAKATSU. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.[J]. American journal of physiology. Gastrointestinal and liver physiology, 2015: G42-51. DOI: 10.1152/ajpgi.00443.2014
[6] JOSEPHE A HONORAT. Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner.[J]. PLoS ONE, 2017: e0187215. DOI: 10.1371/journal.pone.0187215
Febuxostat-d9 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32468 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39037 | 58 |
| Artis Biotech Co. Ltd. | 18108108965 18108108965 | sales@artisbio.com | China | 2451 | 58 |
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chemsky (shanghai) International Co.,Ltd | 021-50135380 | shchemsky@sina.com | China | 15402 | 60 |
| Bide Pharmatech Ltd. | 400-164-7117 18317119277 | product02@bidepharm.com | China | 40000 | 60 |
| Quality Control Solutions Ltd. | 0755-66853366 13670046396 | orders@qcsrm.com | China | 18190 | 56 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9804 | 58 |
| Guangzhou QiYun Biotechnology Co., Ltd. | 020-61288194 61288195 | 505721671@qq.com | China | 3866 | 58 |
| Clearsynth Canada Inc. | +1.415.685.4395 | enquiry@clearsynth.com | Canada | 912 | 58 |
View Lastest Price from Febuxostat-d9 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-04-20 | Febuxostat-D9
1246819-50-0
|
10g | TargetMol Chemicals Inc. |
-
- Febuxostat-D9
1246819-50-0
- TargetMol Chemicals Inc.
1246819-50-0(Febuxostat-d9)Related Search:
1of4
